Phase II study of docetaxel and vinorelbine as adjuvant chemotherapy for resected non-small cell lung cancers Journal Article
| Authors: | Chaft, J. E.; Rekhtman, N.; Sima, C. S.; Rusch, V.; Kris, M. G.; Zakowski, M.; Azzoli, C. G. |
| Article Title: | Phase II study of docetaxel and vinorelbine as adjuvant chemotherapy for resected non-small cell lung cancers |
| Abstract: | Purpose: For patients with resected stage II-III non-small cell lung cancers (NSCLCs), adjuvant cisplatin-based chemotherapy improves survival over surgery alone. For cisplatin ineligible patients, there is no standard adjuvant option. We evaluated drug delivery and toxicity of docetaxel and vinorelbine in patients who could not receive cisplatin. Methods: Patients with completely resected stage IB-III NSCLCs were treated with up to 4 cycles of docetaxel and vinorelbine at the recommended phase II dose. The primary endpoint was drug delivery compared to historical delivery of adjuvant cisplatin plus vinorelbine. Secondary endpoints were toxicity and feasibility. Results: Twenty-five patients were enrolled. Overall, 13/25 (52 %, 95 % CI 34-70) completed 4 cycles, and 19/25 (76 %, 95 % CI 60-87) completed ≥3 cycles. Twenty of 25 patients (80 %) experienced a Grade 3 or 4 adverse event. Conclusions: Delivery of this dose and schedule of docetaxel and vinorelbine was difficult with a dose delivery comparable to cisplatin plus vinorelbine, and cisplatin plus docetaxel, used in this setting. © 2013 Springer-Verlag Berlin Heidelberg. |
| Keywords: | docetaxel; adjuvant chemotherapy; vinorelbine; early-stage non-small cell lung cancer |
| Journal Title: | Cancer Chemotherapy and Pharmacology |
| Volume: | 72 |
| Issue: | 4 |
| ISSN: | 0344-5704 |
| Publisher: | Springer |
| Date Published: | 2013-10-01 |
| Start Page: | 931 |
| End Page: | 934 |
| Language: | English |
| DOI: | 10.1007/s00280-013-2263-1 |
| PROVIDER: | scopus |
| PUBMED: | 23975243 |
| PMCID: | PMC3841970 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 1 November 2013" - "CODEN: CCPHD" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work